AUG 18, 2026 · JOURNAL ARTICLE
Institutional and national Budget impact of alternative pembrolizumab dosing in non-small cell lung cancer: a real-world Pharmacoeconomic Analysis
Expert Review of Pharmacoeconomics & Outcomes Research
A single-center retrospective pharmacoeconomic model with simulated dosing strategy and no clinical outcome data; findings require prospective validation before implementation.
Reported
Institutional drug consumption re…25%
Annual institutional savings>€1.1 million
National extrapolated annual savi…€3.7–11.2 million